No black box warning on record for Nulojix

As of the latest FDA labeling reviewed, Nulojix (BELATACEPT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Nulojix medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Post-Transplant Lymphoproliferative Disorder (PTLD) : increased risk, predominantly involving the CNS; monitor for new or worsening neurological, cognitive, or behavioral signs and symptoms. (Boxed Warning , 4 , 5.1 , 5.6) • Other malignancies : increased risk with all immunosuppressants; appears related to intensity and duration of use. Avoid prolonged exposure to UV

No black box warning on record for Nulojix

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Post-Transplant Lymphoproliferative Disorder (PTLD) : increased risk, predominantly involving the CNS; monitor for new or worsening neurological, cognitive, or behavioral signs and symptoms. (Boxed Warning , 4 , 5.1 , 5.6) • Other malignancies : increased risk with all immunosuppressants; appears related to intensity and duration of use. Avoid prolonged exposure to UV

Nulojix Black Box Warning

No black box warning on record for Nulojix

Other warnings & precautions

Nulojix Black Box Warning

No black box warning on record for Nulojix

Other warnings & precautions